Moleculin Biotech Q1 net loss widens as R&D costs rise

Moleculin Biotech

15/05/2026 13:44

Overview

US clinical-stage pharma reported no Q1 revenue and a wider net loss

Company achieved first 45-subject enrollment milestone in pivotal MIRACLE trial for AML

Q1 research and development expenses rose, mainly due to expanded MIRACLE clinical trials

Outlook

Company expects to unblind MIRACLE trial data for 45 subjects in Q2 2026

Moleculin anticipates recruiting 90 MIRACLE trial subjects and unblinding data in Q3 2026

Company expects current cash resources to support operations into Q3 2026

Result Drivers

MIRACLE TRIAL SPENDING - Co said higher Q1 research and development costs were mainly due to expanded MIRACLE clinical trials in Europe and other research activities

TRIAL ENROLLMENT PROGRESS - Co reported achieving first 45-subject enrollment milestone in pivotal MIRACLE trial for AML, with continued enrollment on pace

Company press release: ID:nGNX4Nn8vj

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 EPS
-$3.54


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Moleculin Biotech Inc is $22.00, about 900% above its May 14 closing price of $2.20

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)